Combination Immunotherapy with Inhibitor of Apoptosis (IAP) Antagonists to Treat Neuroblastoma
Neuroblastoma is the third most common pediatric cancer. Dinutuximab is a recently approved monoclonal antibody targeting GD2, a ganglioside ubiquitously present on neuroblastoma. Recent studies have shown that αGD2 therapy activates PD1-PDL1 signalling, resulting in the inhibition of its full thera...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en |
| Published: |
Université d'Ottawa / University of Ottawa
2019
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10393/38739 http://dx.doi.org/10.20381/ruor-22991 |